Drug Profile
HIV-1 gene therapy - Takara
Alternative Names: MazF gene therapy - TakaraLatest Information Update: 12 Sep 2019
Price :
$50
*
At a glance
- Originator Takara Bio; University of Pennsylvania
- Class Antivirals; Gene therapies
- Mechanism of Action Gene transference; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 03 May 2016 University of Pennsylvania completes enrolment in a phase I trial for HIV-1 infections in USA (NCT01787994)
- 09 Jan 2013 Phase-I clinical trials in HIV-1 infections in USA (IV)
- 01 Dec 2012 No development reported - Phase-I for HIV-1 infections in USA (IV) (NCT01787994)